03 Profile
Hansard to 11 November 2026 · 31,429 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Clinician · Rare diseases
Ianthe Pitout
Dr, molecular geneticist, Murdoch University Personalised Medicine Centre
press citation on 1 topic since 10 Nov 2026 · last quoted 10 Nov 2026
02 Quoted on · 1 of 29 topics
Ianthe Pitout: key facts
- Kind of voice
- Clinician
- Role
- Dr, molecular geneticist, Murdoch University Personalised Medicine Centre
- Quoted on
- Rare diseases
- Tracked press citations
- 1
- Most recently quoted
- 10 Nov 2026
04 The signal · where Ianthe Pitout sits on rare diseases
Ranked 49= of 100 voices quoted in the press on rare diseases, level with 51 others on 1 citation.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1Giles LomaxSector leaderChief Executive Officer, Spinal Muscular Atrophy UK (SMA UK)9
- 2Dr Harrison CarterAcademicDirector of Screening at NHS England8
- 3=
Prof Dame Sue HillRegulatorChief Scientific Officer for England and Senior Responsible Officer for Genomics, NHS England7 - 49=Eleanor ThomasAcademicMD, PhD, assistant professor of neurology at Emory University School of Medicine and co-principal investigator of the study1
- 49=Gonzalo Olmedo-SauraAcademicResearcher, Movement Disorders Research Group, Institut de Recerca Sant Pau; first author of the study1
- 49=Ianthe PitoutClinicianDr, molecular geneticist, Murdoch University Personalised Medicine Centre1
- 49=Jesús Pérez-PérezAcademicResearcher, Movement Disorders Research Group, Institut de Recerca Sant Pau; first author of the study1
- 49=Jonathan GlassAcademicMD, director of the Emory ALS Center and co-principal investigator of the study1
Showing the leaders and the ranks around 49=, of 100 voices · See every voice on the topic →
05 On the record · press
What Ianthe Pitout has said
- technologynetworks.com1
Where Ianthe Pitout has been quoted
- 01Patient-Derived Neuron Models Support Development of MND Therapytechnologynetworks.com · 10 Nov 2026
Verbatim
“Testing the drug in patient-derived cells is more meaningful than standard laboratory tests, because the cells carry the same genetic fault as the patient”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
- Coventry tot's heartbreaking health battle after 'extremely rare' diagnosiscoventrytelegraph.net
- Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdlereuters.com
- 'Immoral lottery' - Mum's plea after losing daughter to rare diseasethewestmorlandgazette.co.uk
Doctors, nurses, allied health professionals and other registered clinicians quoted in a clinical capacity. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 12 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.